In part 3 of this Exclusive Interview, Dr. Francine Kaufman talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about preparing for release of the system first to the Priority Access patients, then to patients at large.
Dr. Francine Kaufman was named Chief Medical Officer and Vice President of Global Medical, Clinical and Health Affairs in April 2009. In this role, Dr. Kaufman is the key architect of the company’s global diabetes strategy, as well as a leading voice for multidisciplinary medical strategy across Medtronic.
Transcript of this video segment:
Steve: So, I understand that you are releasing the new pump gradually, it’s not going out to everybody overnight. Where are you as far as it goes with your patient base?
Dr. Kaufman: So, we are announcing, as a matter of fact I think either today or tomorrow so by the time this is out it will already be announced, that we are now going to the rest of our Priority Access patients, so they bought our 630G system, they will be able to turn that in and get a 670G system. I think there’s an upfront of $299 and they can actually do some things to get that money back by answering surveys and uploading it to the Carelink, so if they wanted to, in the end, it would cost them $0 to upgrade. But there are 30,000 people who have signed up for that, so it’s going to take us awhile. We just finished what we cause a patient learning phase where we wanted to be sure the materials we’ve developed are adequate; we want to be sure we’ve got all the health care providers out there educated; our helpline is ready, new system, people are going to call a lot more. So, we saw that with 700 patients, we watched the data. The data is essentially week-to-week equivalent to what we have seen in our pivotal trial. So ready to go on with these other patients who’ve been waiting. We’re hoping that we’ll be done with that by maybe mid fall and then we’ll be ready for whoever else wants to buy the system after that.